COVID-19. covid-19 virus identified
Conditions
Interventions
Intervention 1: Intervention group: This group will receive Atazanavir (300 mg)\ Ritonavir (100 mg) twice a day - Dolutegravir (500 mg) once a day and Hydroxychloroquine (400 mg BD for the first day a
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Having three or more of the following conditions:(1) Cough (2) weakness (3) fever of =38.5°C (4) Intense fatigue (5) myalgia (6) sore throat (7) Dyspnea (8) Low appetite/Diarrhea/nausea (9) Decreased awareness Or having one or more of the following disease characteristics: (1) Oxygen saturation value of less than 93% (2) disease confirmation based on chest imaging results (3) A respiratory rate greater than 24 breaths per minute
Exclusion criteria
Exclusion criteria: Negative COVID-19 specific PCR test result Patients that are well enough to not need hospitalization
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Death. Timepoint: During treatment. Method of measurement: Clinical.;ICU admission. Timepoint: During treatment. Method of measurement: Clinical.;Intubation. Timepoint: During treatment. Method of measurement: Clinical. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSaeed Kalantari
Iran University of Medical Sciences
Outcome results
None listed